Condition 1: major thalasemia. Condition 2: intermedia thalasemia. Beta thalassemia Beta thalassemia
Conditions
Interventions
Intervention 1: Intervention group: The group that receives Jadenu. Jadenu is part of the drug class deferasirox . 33 people are being treated with Deferasirox (Jadenu®) for 6 months. This drug will b
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
2 Years to 50 Years
Inclusion criteria
Inclusion criteria: Age over 2 years Patients diagnosed with thalassemia major and intermedia Having conscious satisfaction Serum ferritin above 1000 µg / mL
Exclusion criteria
Exclusion criteria: Existence of contraindications to the studied drugs (Exjade®) and (Jadenu®) Patients with GFR ?40 mL / min / 1.73 m2 Patients with stunted growth Patients at high risk for myelodysplasia syndrome (MDS) Advanced cancer Platelets below 50 x 109 / L Patients with knowledge of sensitivity to drugs of the defrazirox group Patients with liver failure Patients with gastrointestinal bleeding Patients with renal insufficiency Simultaneous use of other iron chelators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum ferritin. Timepoint: Sampling every two months. Method of measurement: The patient's serum is separated by centrifuge and given to an auto-analyzer.;Serum creatinine. Timepoint: Sampling every two months. Method of measurement: The patient's serum is separated by centrifuge and given to an auto-analyzer.;Serum BUN. Timepoint: Sampling every two months. Method of measurement: The patient's serum is separated by centrifuge and given to an auto-analyzer. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactVahid Falahati
Arak University of Medical Sciences
Outcome results
None listed